Acer Therapeutics Inc., a Cambridge, MA-based pharmaceutical company developing therapies for serious rare diseases, closed its $8.15m Series B round.
The round was led by TVM Life Science Venture VII, with participation from Bukwang Pharm. Co. In conjunction with the funding, Dr. Luc Marengere, Managing Partner of TVM Life Science Capital, joined Acer’s board.
Led by Chris Schelling, CEO and founder, Acer is developing therapies with established clinical proof-of-concept for the treatment of serious, ultra-rare diseases with critical unmet medical need.
The company’s late-stage clinical pipeline includes two candidates for severe genetic disorders for which there are currently no FDA-approved treatments:
– ACER-002 for vascular Ehlers-Danlos Syndrome (vEDS), a rare, life-threatening genetic connective tissue disorder, and
– ACER-001, a proprietary taste-masked, immediate-release formulation of sodium phenylbutyrate (NaPBA) for Maple Syrup Urine Disease (MSUD) and Urea Cycle Disorder (UCD), serious genetic diseases which impact amino acid and ammonia metabolism.
The company, which has raised $12.25m in Series A and Series B rounds to date, intends to use the proceeds to prepare a new drug application (NDA) for its ACER-002 and – ACER-001, which have both received orphan drug designation from the U.S. Food and Drug Administration (FDA).